Related Experiment Video
Updated: Jul 13, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Management guidelines for mucopolysaccharidosis VI.
Roberto Giugliani1, Paul Harmatz, James E Wraith
1Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Pediatrics
|August 3, 2007
Summary
Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) is a rare lysosomal storage disease. Comprehensive management guidelines are now available to aid in the diagnosis and treatment of this complex condition.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) is a rare lysosomal storage disease.
- It presents with diverse systemic clinical manifestations and functional impairments.
- Diagnosis and management are complicated by significant variability in symptom presentation and disease progression.
Purpose of the Study:
- To establish comprehensive management guidelines for Mucopolysaccharidosis VI.
- To provide evidence-based recommendations for optimal patient care.
- To support clinicians in diagnosing and managing patients with Maroteaux-Lamy syndrome.
Main Methods:
- Development of guidelines by an international expert group.
- Inclusion of evidence from randomized controlled trials, meta-analyses, systematic reviews, and expert opinion.
- Detailed outline of disease manifestations and treatment options.
Main Results:
- Guidelines offer a systematic approach to Mucopolysaccharidosis VI management.
- Recommendations cover regular patient assessments across body systems.
- An overview of current therapeutic strategies is provided.
Conclusions:
- These guidelines represent a crucial resource for managing Mucopolysaccharidosis VI.
- Standardized care based on expert consensus can improve patient outcomes.
- The document facilitates evidence-based decision-making for clinicians.
Related Concept Videos
01:23Glycosaminoglycans
Glycosaminoglycans (GAGs), also known as mucopolysaccharides, are long and linear polymers comprising of specific repeating disaccharides - the amino sugar that can be N-acetylglucosamine or N-acetylgalactosamine, and a uronic acid that is usually glucuronic acid or iduronic acid.
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
01:05Proteoglycans
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...